Search Results for “EC” – Page 214 – media

3D Pathology with AI to Enhance Prognosis Accuracy for Barrett’s Esophagus Patients

Barrett’s esophagus is a condition where the lining of the esophagus changes due to chronic gastroesophageal reflux. Individuals with Barrett’s esophagus are at a slightly increased risk of developing esophageal cancer and require regular surveillance endoscopies. During these procedures, gastroenterologists collect numerous biopsies from the affected tissues. These samples are then cut into thin sections and placed on glass slides for examination under a microscope by pathologists. However, the tissue sections that pathologists view represent only about 1% or less of the actual biopsies and provide just a two-dimensional view, which can be misleading. Researchers are now conducting clinical studies of archived tissues from patients with the condition to develop computational 3D pathology methods for Barrett’s esophagus risk stratification. The research team at UW College of Engineering (Seattle, WA, USA) had previously invented 3D pathology methods to assess prostate cancer risk and shifted their focus on gastrointestinal applications of their ...
- Source: drugdu
- 57
- August 10, 2024
FCE Pharma

Organiser：Nuremberg Exhibition Co. LTD Time：June 10th – 12th, 2025 address：Centro de Exposições Imigrantes, Rodovia dos Imigrantes, Km 1,5 São Paulo – SP Exhibition hall：São Paulo Expo Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, Hormones, Antipyretics and Analgesics, Medicines for Digestive System, Anti-infective Drugs, Antiparasitic Drugs, Cardiovascular Drugs, Intermediates Medical Devices: Pharmaceutical Packaging Materials, PVC/PVDC Laminates, PVC Rigid Sheets, PS Sheets, Packaging Anti-counterfeiting Technology Information, Labeling and Sleeve Labeling Technology, LabelFilling Machines, Packaging Container Forming, Filling, and Sealing Machines, Wrapping Machines, Paper Film Packaging Machinery, etc. Others: Large Infusion Equipment Production Lines, Dryers, Water Treatment Equipment, Refrigeration Compressors, Distillation Equipment, Sterilization Equipment, Tablet Presses, Coating Machines, Plastic Processing Equipment, Crystallization Equipment, etc. About FCE Pharma： FCE Pharma – the International Pharmaceutical Ingredients and Pharmaceutical Exhibition in São Paulo, Brazil, is the premier pharmaceutical technology exhibition in South America. It plays a pivotal role in the development of the pharmaceutical ...
- Source: drugdu
- 322
- August 9, 2024
China moves to advance high-quality development of service consumption

China will work to further develop consumer services to support high-quality economic development and meet people’s demand for personalized, diversified and quality services, according to a guideline made public Saturday. The guideline, issued by the State Council, set out 20 key tasks, including tapping the potential of consumption in sectors such as hospitality, domestic services, elderly care, childcare, entertainment, tourism, sports, education and training. It also pledged to foster new types of consumption like digital, green and health services, create new consumption scenarios, relax market access, strengthen regulation and provide more policy support for service consumption. China will continue to open up sectors such as telecommunications, education, elderly care and medical care, and ensure the implementation of opening-up measures in areas like technology services and tourism, according to the document. The country will also optimize entry policies and consumption environments, speed up the resumption of flights, provide diversified payment services, ...
- Source: drugdu
- 96
- August 9, 2024
Janssen’s psoriasis drug shows promise for childhood diabetes

A new study led by researchers from Cardiff University, King’s College London (KCL), Swansea University and the University of Calgary has revealed that Janssen’s psoriasis drug, Stelara (ustekinumab), shows promise in treating childhood diabetes. Published in Nature Medicine and funded by a Medical Research Council and National Institute for Health and Care Research partnership, the study found that Stelara was more effective in treating the early stages of type 1 diabetes (T1D) in children and adolescents. Accounting for approximately 10% of diabetes cases in the UK, T1D occurs when the pancreas does not produce insulin or makes very little insulin. Since 2009, the immunotherapy Stelara has been used to treat psoriasis, a skin condition characterised by flaky patches of skin that affects around 60 million people globally, as well as other immune conditions, including psoriatic arthritis, severe Crohn’s disease and severe ulcerative colitis. In the study, researchers tested Stelara in ...
- Source: drugdu
- 65
- August 9, 2024
MRC and MND Association award £3.9m to KCL and UCL for ALS/FTD research

The Medical Research Council and the Motor Neurone Disease (MND) Association have awarded researchers from King’s College London (KCL) and University College London (UCL) £3.9m to investigate an early disease pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The team aims to explore and systematically investigate the axonal dysfunction in neurodegeneration and design therapeutic strategies to address the disease at an early stage. Axonal dysfunction occurs when there is a complete degeneration of axons – parts of the neurons that allow them to carry signals and transmit information to other cells. These results are seen in neurodegenerative diseases such as ALS and FTD. ALS is a fatal type of MND that causes progressive degeneration of nerve cells in the spinal cord and brain, while FTD is the result of damage to neurons in the frontal and temporal lobes of the brain. Combined, these conditions are estimated to affect ...
- Source: drugdu
- 67
- August 9, 2024
Novel Cervical Cancer Screening Method to Reduce Need for Invasive Procedures

Cervical cancer remains a significant global health issue, with about 500,000 new cases identified annually. The incidence of cervical intraepithelial neoplasia (CIN), or precursor lesions to cervical cancer, is even more common, occurring 20 times as frequently. Timely detection of these conditions is crucial for effective treatment and improved patient outcomes, underscoring the importance of advancing screening techniques for CIN and cervical cancer. The primary methods currently employed are the human papillomavirus (HPV) test and cytology examination. While cytology is a longstanding method with widespread use, its sensitivity for detecting CIN is relatively low. Conversely, while HPV tests are highly sensitive, they often lack specificity since not all HPV infections lead to cervical lesions. This underscores the pressing need for more refined diagnostic approaches. Against this backdrop, researchers at Fujita Health University (Aichi, Japan) have been exploring biomarkers that could facilitate the early detection of cervical cancer. Their latest findings, ...
- Source: drugdu
- 87
- August 8, 2024
Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer

The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8 billion acquisition of Agios Pharmaceuticals’ oncology business. By Frank Vinluan A Servier Pharmaceuticals drug designed to penetrate the brain to hit its targets is now FDA approved for treating two rare types of brain cancer. The FDA approval announced Tuesday covers the treatment of adults and adolescents 12 and older who have Grade 2 astrocytoma or oligodendroglioma. The drug, vorasidenib, may be prescribed after surgery, as long as the cancers have mutations to the IDH1 or IDH2 enzymes the once-daily pill is designed to inhibit. The FDA said this regulatory decision marks the agency’s first for a systemic therapy for these cancers driven by either the IDH1 or IDH2 mutations. France-based Servier, which has its U.S. headquarters in Boston, will commercialize ...
- Source: drugdu
- 70
- August 8, 2024
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China

Luye Pharma Group today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for LY03020 filed under the Class 1 pathway for investigational drugs. LY03020, a dual TAAR1/5-HT2CR agonist, is intended to treat schizophrenia and Alzheimer’s disease psychosis (ADP). Developed on Luye Pharma’s New Chemical Entity/New Therapeutic Entity (NCE/NTE) platform, LY03020 is a next-generation antipsychotic and the first agonist against both the trace amine-associated receptor 1 (TAAR1) and the 5-HT2C receptor (5-HT2CR) in the world. “Unlike the existing antipsychotics that typically antagonize D2 and 5-HT2A receptors on the postsynaptic membrane, the next-generation antipsychotics agonize those receptors on the presynaptic membrane. Compared with the existing antipsychotics, LY03020 targets both TAAR1 and 5-HT2CR, and thus is able to reduce adverse reactions such as extrapyramidal symptoms (EPS) and metabolic syndromes while significantly improving the negative symptoms and cognitive impairments ...
- Source: drugdu
- 73
- August 8, 2024
Researchers reveal brain parasites could be used to treat cognitive disorders

Researchers from the University of Glasgow, in collaboration with Tel Aviv University, along with international researchers, have revealed that brain parasites could be used to deliver drugs to the brain to treat cognitive disorders. In the study published in Nature Microbiology, researchers explored whether the common brain parasite Toxoplasma gondii could be used to deliver treatment across the blood-brain barrier, a major complication for the treatment of many neurological conditions. According to a study published in the Lancet Neurology in March and funded by the Bill & Melinda Gates Foundation, neurological conditions are considered the leading cause of ill health worldwide, with stroke, neonatal encephalopathy, migraine, Alzheimer’s disease (AD) and other dementias, and diabetic neuropathy being the biggest global contributors. Researchers engineered Toxoplasma gondii parasites to deliver the MeCP2 protein, a therapeutic protein that has been dubbed a promising target for Rett syndrome, a debilitating neurological disorder caused by mutations in ...
- Source: drugdu
- 60
- August 8, 2024
FDA Approves Expanded Indication for Octapharma’s Fibryga for Patients Experiencing Bleeding Due to Acquired Fibrinogen Deficiency

By Don Tracy, Associate Editor Expanded indication makes Fibryga the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication.The FDA has approved an expanded indication for Octapharma’s Fibryga, a lyophilized human fibrinogen concentrate now indicated for patients experiencing bleeding due to acquired fibrinogen deficiency (AFD). According to the company, this approval marks a significant advancement over cryoprecipitate, the current standard of care, by providing a faster and more precise treatment option for severe bleeding episodes. Additionally, the regulatory action makes Fibryga the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication.1 “In the surgical theater, time matters. And confidence matters. This expanded FDA approval of fibryga represents a major step forward in our commitment to redefining the standard of care for patients experiencing major bleeding. It provides an important option for providers who must act urgently,” said Flemming Nielsen, president, Octapharma USA, ...
- Source: drugdu
- 83
- August 7, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.